Reviews

Genetic risk factors in Alzheimer’s disease

L Tilley, K Morgan, N Kalsheker

Abstract
Following a brief introduction and discussion of the pathological features of Alzheimer’s disease, the main emphasis of this review article will be the genetic factors that have been implicated in this disease. These can be divided into two main categories. First, the three genes in which mutations are known to result in early onset autosomal dominant familial Alzheimer’s disease will be discussed. These are well characterised but account for only a small proportion of Alzheimer’s disease cases. Late onset, sporadic Alzheimer’s disease is more common and evidence suggests that there is a genetic component to this type of disease. A number of genetic risk factors have been implicated that might increase the risk of developing sporadic disease. Many of these are controversial and studies have shown conflicting results, which are discussed in this section. Finally, a brief discussion of some of the mechanisms suggested to play a role in the pathogenesis of Alzheimer’s disease is included. It is hoped that this will show why particular genes have been implicated in Alzheimer’s disease and how they might be able to influence the development of the disease. (J Clin Pathol: Mol Pathol 1998;51:293–304)

Keywords: Alzheimer’s disease; susceptibility genes; genetic risk factors

Alzheimer’s disease is a progressive neurodegenerative disorder, first described by Alois Alzheimer.1 It is the leading cause of dementia in the elderly, accounting for around 50% of all dementias. The remaining 50% are caused by ~70 different disorders, but comprise mainly Lewy body dementia (20–30%) and multi-infarct dementia (10–20%), with the final 10% being the atypical dementias such as Pick’s disease, Huntington’s disease, and Creutzfeldt-Jacob’s Disease (CJD). Estimates of the prevalence of Alzheimer’s disease are variable, probably because of uncertainty in diagnosis, but increase from 0.3% in the 60–69 year age group, to more than 10% in those over 80 years of age.2 It is estimated that there are more than 600 000 people in the UK suffering from the disease.

Alzheimer’s disease is characterised by progressive dementia beginning in middle to late life, with death occurring an average of 8–10 years after diagnosis.3 The clinical manifestations of the disease are extremely variable, with symptoms including memory loss, confusion, personality changes, impaired coordination, and speech problems.

Alzheimer’s disease can be categorised according to its age of onset or mode of inheritance. The early onset disease is defined as having an age of onset before 65 years of age, and these cases are usually familial, being inherited in an autosomal dominant fashion. This type of Alzheimer’s disease, known as familial Alzheimer’s disease is rare, accounting for ~10% of all Alzheimer’s disease cases. Most Alzheimer’s disease cases are of the late onset type, occurring in individuals over 65 years of age, and are sporadic, with no strong family history.

Pathological features of Alzheimer’s disease
Pathologically, the Alzheimer’s disease brain is characterised by two types of lesion: senile or neuritic plaques and neurofibrillary tangles. It has been shown that intellectual decline correlates with the densities of neurofibrillary tangles and senile plaques in the diseased brain.4 It is believed that the formation of these lesions is likely to result in the destruction of cell bodies, dendrites, and synapses, thus leading to severe impairment of neurotransmission and resulting in a decline in cognitive abilities.

SENILE PLAQUES
Senile plaques consist of a spherical extracellular core of proteinaceous fibrillar deposits, or amyloid, surrounded by degenerating nerve cell processes (fig 1). They are found particularly in the hippocampus, neocortex, and amygdala, and in the walls of cerebral and meningeal blood vessels. The predominant protein in the senile plaque core is a 4 kDa peptide,5 known as Aβ, β-amyloid, A4, or β/A4. Aβ contains between 39 and 43 amino acids, differing at the C-termius, with the 42 amino acid form being the most predominant form in amyloid deposits.6 Aβ is derived from a larger precursor protein known as the amyloid precursor protein (βAPP) via proteolytic cleavage.7,8

In addition to Aβ, a number of other senile plaque components have been identified. The
The genetic basis of Alzheimer's disease is complex and multifactorial. Familial Alzheimer's disease (FAD) is characterized by autosomal dominant inheritance, with early onset in individuals typically in their 30s to 60s. The disease is associated with specific mutations in the genes encoding the amyloid precursor protein (APP) and presenilin 1 (PS-1) or 2 (PS-2) proteins. These mutations result in altered metabolism of APP, leading to increased production of amyloid beta (A\beta) peptides and formation of amyloid plaques. The PS-1 protein is homologous to Caenorhabditis elegans SEL-12, a protein known to be involved in cell signalling during development.

**NEUROFIBRILLARY TANGLES**

Neurofibrillary tangles are abnormal proteinaceous deposits, which form as intraneuronal inclusions but become externalized as their neuronal source degenerates (fig 2). They occur in cell bodies and apical dendrites of degenerating neurons surrounding the core of senile plaques. Neurofibrillary tangles are a common feature of dystrophic neurons and are not specific to Alzheimer’s disease, also being characteristic of other neurodegenerative diseases, such as Parkinson’s disease. Their main structural component is an abnormal fibre known as a paired helical filament. It is likely that the sole component of these paired helical filaments is a hyperphosphorylated form of the microtubule associated protein tau. Hyperphosphorylated tau in neurofibrillary tangles is also known to be ubiquitinated, suggesting a role for the ubiquitin dependant proteolysis pathway in Alzheimer’s disease.

**Table 1**

<table>
<thead>
<tr>
<th>Chromosomal location</th>
<th>Gene</th>
<th>Estimated FAD cases</th>
<th>Age of onset (years)</th>
<th>No. of mutations</th>
<th>Possible mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>21q21.1</td>
<td>APP</td>
<td>Up to 5%</td>
<td>43-62</td>
<td>6</td>
<td>Altered APP processing</td>
</tr>
<tr>
<td>14q24</td>
<td>PS-1</td>
<td>Up to 80%</td>
<td>29-62</td>
<td>35+</td>
<td>Increase in A\beta, A\beta-A\alpha</td>
</tr>
<tr>
<td>1q31-42</td>
<td>PS-2</td>
<td>~20%</td>
<td>40-88</td>
<td>2</td>
<td>Increase in A\beta-A\alpha</td>
</tr>
</tbody>
</table>

APP, amyloid precursor protein; PS-1, presenilin 1.

**Genetics of Alzheimer's disease**

In a number of families Alzheimer’s disease is inherited as an autosomal dominant disorder, although in most cases inheritance appears to be multifactorial. Monozygotic twin studies indicate a variable concordance of between 18%\(^\text{16}\) and 41%\(^\text{15}\), showing that Alzheimer’s disease cannot be explained completely by a single autosomal dominant gene. A relative risk of 3.5 has been demonstrated for those with at least one first degree relative suffering from dementia.\(^\text{17}\)

**Autosomal dominant gene mutations**

Three genes have been identified to date in which mutations result in early onset familial Alzheimer’s disease, inherited in an autosomal dominant fashion. These are the amyloid precursor protein (APP), presenilin 1 (PS-1), and PS-2 genes (table 1).

**THE APP GENE**

The APP gene maps to chromosome 21q21.1\(^\text{6}\) and mutations in this gene are estimated to account for up to 5% of familial Alzheimer’s disease cases. A number of mutations have been identified, at codons 717\(^\text{18-20}\), 670/671\(^\text{21}\), 692\(^\text{22}\) and 693\(^\text{23}\). Mutations in the APP gene lead to early onset disease with age of onset typically between 43 and 62 years.\(^\text{24}\)

Mutations in the APP gene might result in altered metabolism of APP, leading to increased production of the A\beta protein, or an increased production of the 42 amino acid form of A\beta (A\beta\text{1-42}). This is the predominant form in senile plaques, and is thought to be more amyloidogenic, forming amyloid fibrils more rapidly than the shorter forms of A\beta.\(^\text{6}\)

**THE PS-1 GENE**

A second familial Alzheimer’s disease locus was identified by genetic linkage analysis at chromosome 14q24.\(^\text{25-27}\) The gene responsible was subsequently identified as S182 or PS-1, and mutations in this gene are thought to cause up to 80% of familial Alzheimer’s disease cases, with onset as early as 29 years of age,\(^\text{28}\) ranging to 62 years of age.\(^\text{24}\) To date, more than 35 missense mutations, and one in frame deletion,\(^\text{29}\) have been identified in the PS-1 gene in affected families.

The fact that most PS mutations are missense ones suggests that Alzheimer’s disease pathology is a result, not of the absence of the PS-1 gene product, but of its abnormal functioning as a result of the mutation. The function of the PS-1 protein is unknown, but it is known to be a transmembrane protein and, therefore, might function as a cell surface receptor, ion channel, or membrane structural protein.\(^\text{30}\) The PS-1 protein is homologous to SEL-12 in Caenorhabditis elegans,\(^\text{18}\) a protein known to be involved in cell signalling during development. The PS-1 gene product is known to be essential during development because
Genetic risk factors in Alzheimer’s disease

PS-1 gene knockout mice exhibit skeletal deformations, impaired neurogenesis, and neuronal cell death, leading to death shortly after birth.32 33

THE PS-2 GENE

Although mutations in the PS-1 gene account for most cases of familial Alzheimer’s disease, there are some affected families in which both APP and PS-1 mutations have been excluded. A third locus was identified at chromosome 1q31–42,34 and the mutated gene was identified subsequently as STM-2 or PS-2.35 Only 1q31–42,34 and the mutated gene was identified subsequently as STM-2 or PS-2.35

A third locus was identified at chromosome 1q31–42,34 and the mutated gene was identified subsequently as STM-2 or PS-2.35

Although mutations in the PS-1 gene account for most cases of familial Alzheimer’s disease, there are some affected families in which both APP and PS-1 mutations have been excluded. A third locus was identified at chromosome 1q31–42,34 and the mutated gene was identified subsequently as STM-2 or PS-2.35 Only 1q31–42,34 and the mutated gene was identified subsequently as STM-2 or PS-2.35

Mutations in the PS-1 gene cause over production of Aβ1–42 production, even in the presence of wild-type alleles. It has also been reported that PS-1 mutations lead to altered protein metabolism, resulting in accumulation of N-terminal and C-terminal PS-1 protein fragments in brains of transgenic mice.36 However, it is not clear how this accumulation of fragments contributes to neurodegeneration.

Susceptibility genes

Only a small proportion (~10%) of Alzheimer’s disease cases are caused by mutations inherited in an autosomal dominant fashion. Most cases are late onset and apparently sporadic, probably as a result of a combination of environmental and non-dominant genetic factors. A number of genetic risk factors have been implicated in Alzheimer's disease, which are not sufficient to cause the disease, but may greatly increase the risk above that of the general population; these are susceptibility genes (table 2).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chromosomal location</th>
<th>Risk factor</th>
<th>Onset</th>
<th>Familial/sporadic</th>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOE</td>
<td>19q13.2</td>
<td>ε4 allele</td>
<td>LOAD and EOAD</td>
<td>Familial and sporadic</td>
<td>APOE ε4 independent</td>
</tr>
<tr>
<td>APOE</td>
<td>19q13.2</td>
<td>~491 A allele</td>
<td>LOAD</td>
<td>Sporadic</td>
<td>In APOE ε4 carriers only</td>
</tr>
<tr>
<td>VLDL-R</td>
<td>9</td>
<td>Trinucleotide five repeat allele</td>
<td>LOAD</td>
<td>Sporadic</td>
<td></td>
</tr>
<tr>
<td>LRP</td>
<td>12</td>
<td>Exon 3 CC genotype</td>
<td>LOAD</td>
<td>Familial and sporadic</td>
<td>Sporadic</td>
</tr>
<tr>
<td>LRP</td>
<td>12</td>
<td>TTTT repeat polymorphism</td>
<td>LOAD</td>
<td>Sporadic</td>
<td></td>
</tr>
<tr>
<td>A2M</td>
<td>12p</td>
<td>A2M-2 allele</td>
<td>LOAD</td>
<td>Familial</td>
<td>No interaction with APOE</td>
</tr>
<tr>
<td>PS-1</td>
<td>14q24</td>
<td>Intron 8, allele 1</td>
<td>LOAD</td>
<td>Sporadic</td>
<td>In APOE ε4 carriers only</td>
</tr>
<tr>
<td>B3A2</td>
<td>1q26.1–2</td>
<td>K allele</td>
<td>LOAD (over 75 years)</td>
<td>Sporadic</td>
<td></td>
</tr>
<tr>
<td>ACT</td>
<td>1q42.1</td>
<td>Signal sequence A allele</td>
<td>LOAD</td>
<td>Familial and sporadic</td>
<td>In association with APOE ε4</td>
</tr>
<tr>
<td>ACT</td>
<td>14q32.1</td>
<td>Microsatellite A10 allele</td>
<td>LOAD</td>
<td>Sporadic</td>
<td>In association with APOE ε4</td>
</tr>
</tbody>
</table>

EOAD, early onset Alzheimer’s disease; LOAD, late onset Alzheimer’s disease; ACT, α1 antichymotrypsin; A2M, α2 macroglobulin; APOE, apolipoprotein E; BChE, butyrylcholinesterase; LRP, low density lipoprotein receptor related protein; PS-1, presenilin 1; VLDL-R, very low density lipoprotein receptor.

APOLIPOPROTEIN E (APOE) GENE

The gene for apolipoprotein E (apoE) is located in a cluster of apolipoprotein genes at chromosome 19q13.2. This region was first implicated in late onset Alzheimer’s disease by linkage studies.40–42 apoE is a 34 kDa glycoprotein encoded by a polymorphic gene resulting in three common alleles, named ε2, ε3, and ε4. The APOE ε4 allele is a well established risk factor for late onset Alzheimer’s disease, with a significantly higher frequency observed in Alzheimer’s disease cases than in controls.43–45 This association has been confirmed for both familial and sporadic late onset Alzheimer’s disease,44 45 and has also been reported in the early onset disease.46 47

The APOE ε4 risk has been shown to be dose dependant, the risk increasing with the number of ε4 alleles. One study has reported an odds ratio of 2.8 for individuals with one ε4 allele, increasing to 8.1 for individuals homozygous for the ε4 allele, compared with individuals with no ε4 alleles.48 It has also been shown that each ε4 allele lowers the age of onset by seven to nine years in late onset familial Alzheimer’s disease.44 49

A gender difference has been suggested for APOE associated risks50 51 but other studies have failed to confirm this difference.52 53 However, the former studies50 51 only considered data from families, so the proposed sex specific risk might only apply in familial Alzheimer’s disease.

In contrast to the increased risk conferred by possession of the ε4 allele, a protective effect has been proposed for the ε2 allele. It has been observed in several studies that individuals possessing the ε2 allele have a lower incidence of Alzheimer’s disease.53 54 However, other studies have failed to find this association,55 and some studies have conversely suggested that the ε2 allele acts as a risk factor in the early onset disease.56 57

Table 2  Susceptibility genes in which polymorphisms have been reported to influence Alzheimer’s disease risk

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chromosomal location</th>
<th>Risk factor</th>
<th>Onset</th>
<th>Familial/sporadic</th>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOE</td>
<td>19q13.2</td>
<td>ε4 allele</td>
<td>LOAD and EOAD</td>
<td>Familial and sporadic</td>
<td>APOE ε4 independent</td>
</tr>
<tr>
<td>APOE</td>
<td>19q13.2</td>
<td>~491 A allele</td>
<td>LOAD</td>
<td>Sporadic</td>
<td>In APOE ε4 carriers only</td>
</tr>
<tr>
<td>APOE</td>
<td>19q13.2</td>
<td>TATA box T allele</td>
<td>LOAD</td>
<td>Sporadic</td>
<td></td>
</tr>
<tr>
<td>VLDL-R</td>
<td>9</td>
<td>Trinucleotide five repeat allele</td>
<td>LOAD</td>
<td>Sporadic</td>
<td></td>
</tr>
<tr>
<td>LRP</td>
<td>12</td>
<td>Exon 3 CC genotype</td>
<td>LOAD</td>
<td>Familial and sporadic</td>
<td>Sporadic</td>
</tr>
<tr>
<td>LRP</td>
<td>12</td>
<td>TTTT repeat polymorphism</td>
<td>LOAD</td>
<td>Sporadic</td>
<td></td>
</tr>
<tr>
<td>A2M</td>
<td>12p</td>
<td>A2M-2 allele</td>
<td>LOAD</td>
<td>Familial</td>
<td>No interaction with APOE</td>
</tr>
<tr>
<td>PS-1</td>
<td>14q24</td>
<td>Intron 8, allele 1</td>
<td>LOAD</td>
<td>Sporadic</td>
<td>In APOE ε4 carriers only</td>
</tr>
<tr>
<td>B3A2</td>
<td>1q26.1–2</td>
<td>K allele</td>
<td>LOAD (over 75 years)</td>
<td>Sporadic</td>
<td></td>
</tr>
<tr>
<td>ACT</td>
<td>1q42.1</td>
<td>Signal sequence A allele</td>
<td>LOAD</td>
<td>Familial and sporadic</td>
<td>In association with APOE ε4</td>
</tr>
<tr>
<td>ACT</td>
<td>14q32.1</td>
<td>Microsatellite A10 allele</td>
<td>LOAD</td>
<td>Sporadic</td>
<td>In association with APOE ε4</td>
</tr>
</tbody>
</table>

EOAD, early onset Alzheimer’s disease; LOAD, late onset Alzheimer’s disease; ACT, α1 antichymotrypsin; A2M, α2 macroglobulin; APOE, apolipoprotein E; BChE, butyrylcholinesterase; LRP, low density lipoprotein receptor related protein; PS-1, presenilin 1; VLDL-R, very low density lipoprotein receptor.
Recently, two polymorphisms within the APOE gene regulatory regions have been reported to play a role in Alzheimer’s disease. A G/T biallelic polymorphism in the APOE gene TATA box may modulate the influence of the APOE ε4 allele on the risk of disease, whereas an A/T polymorphism at position −491 was associated with Alzheimer’s disease risk independently of APOE ε4 status. Homozygosity for −491A was found to confer an increased risk of disease, possibly by altering the level of apoE protein production. The A allele was associated with higher constitutive levels of APOE promoter activity, as a result of differences in affinity for nuclear proteins between the two alleles. However, a subsequent study has failed to reproduce the association between the −491 regulatory region polymorphism and Alzheimer’s disease, although results suggest that the frequency of the −491 A/T polymorphism may vary considerably between different ethnic groups.

Although the APOE ε4 allele is a well-documented risk factor for Alzheimer’s disease, it is neither necessary nor sufficient for development of the disease. This implicates the involvement of other factors, either genetic or environmental, acting either independently or in association with the APOE ε4 allele. One study has reported that the presence of herpes simplex virus type 1 (HSV-I) DNA in the brain, together with possession of the APOE ε4 allele, is a strong risk factor for Alzheimer’s disease. In addition, various genetic factors have been reported to modify the risk associated with APOE ε4 (see below) but none, as yet, have been as convincing or reproducible in different study groups, as the APOE effect.

**VERY LOW DENSITY LIPOPROTEIN RECEPTOR (VLDL-R) GENE**

Receptors for apoE containing lipoproteins such as the VLDL-R have been proposed to act as risk factors for Alzheimer’s disease, by influencing the metabolism of apoE in the brain. The VLDL-R gene is located on chromosome 9, and contains a polymorphic trinucleotide tandem repeat (CGG), in the 5' untranslated region, with alleles ranging from four to nine repeats. It has been observed in a Japanese population that homozgygosity for the five repeat allele, in association with possession of the APOE ε4 allele, confers an increased risk of developing Alzheimer’s disease above that associated with possession of the APOE ε4 allele alone. However, subsequent studies in white populations have failed to find any association, although there are marked differences in allele frequencies between the Japanese and white populations. Thus, it is possible that the VLDL-R five repeat allele acts as an Alzheimer’s disease risk factor in Japanese populations only, although a further study in a Japanese population has also failed to find any association. It seems unlikely that the VLDL-R polymorphism plays a role in the late onset disease in white populations, but further studies are required to confirm its importance in Japanese populations.

In addition to VLDL-R, other lipoprotein receptors have also been investigated as candidate risk factors for late onset Alzheimer’s disease. Studies of the low density lipoprotein receptor (LDL-R) gene have shown no association with Alzheimer’s disease. The LDL-R related protein (LRP) gene, located on chromosome 12, has also been suggested as a candidate risk factor in the late onset disease. The LRP protein is the main apoE receptor in the brain, and is also responsible for endocytosis of secreted APP, suggesting a possible role in the pathogenesis of Alzheimer’s disease. Studies involving a TTTC repeat polymorphism in the 5' end of the LRP gene have shown conflicting results. Using an alternative marker, a silent C/T polymorphism in exon 3 of the LRP gene, suggest that the CC genotype is over represented in patients with Alzheimer’s disease compared with controls, in both familial and sporadic late onset disease. Linkage data implicating a locus on chromosome 12 in late onset Alzheimer’s disease also suggest that the LRP locus might be important.

**a2 MACROGLOBULIN GENE (A2M)**

a2 Macroglobulin is a serum pan-protease inhibitor that has been implicated in Alzheimer’s disease because of its presence in senile plaques and its ability to bind Aβ, attenuating both fibril aggregation and neurotoxicity. Along with apoE and βAPP, a2 macroglobulin is a major ligand for the LRP receptor, which has also been implicated in Alzheimer’s disease. A splice acceptor deletion in exon 18 of the a2 macroglobulin gene, known as A2M-2, has been reported recently to be associated with an increased risk of Alzheimer’s disease. Using a sibling study approach, the frequency of the A2M-2 allele was found to be higher in probands than in unaffected individuals, with the odds ratio associated with possession of at least one copy of the A2M-2 allele was ∼3.6, similar in magnitude to that associated with homozgyosity for the APOE ε4 allele in this study. These findings are interesting in the light of reports implicating a locus on chromosome 12 associated with Alzheimer’s disease. A2M maps to chromosome 12p, within 30 cM of the implicated chromosome 12 markers. Thus, further study of the A2M gene is justified, and as the odds ratio associated with the A2M-2 allele is similar in magnitude, or larger, than that associated with the APOE ε4 allele, this gene could prove to be an important risk factor in Alzheimer’s disease.

**THE PS-1 GENE**

Although the PS-1 gene is generally thought to be involved only in early onset familial Alzheimer’s disease, allele sharing between affected family members with late onset disease has been observed, suggesting a further role for PS-1 in late onset Alzheimer’s disease. It has been reported that a biallelic polymorphism within intron 8 of the PS-1 gene acts as a risk factor for late onset disease, with homozgyosity for allele 1 being associated with an approximate doubling of risk when
compared with individuals with either one or no copies of allele 1.59 This association has been confirmed in two subsequent studies,60 61 but others have failed to find an association.62–64

**BUTYRYLCHOLINESTERASE (BChE) GENE**

The BChE gene is located at chromosome 3q26.1–26.2. BChE is expressed in most human tissues but its function is unknown. BChE activity in the brain increases in an age dependent fashion after 60 years of age, and is raised in Alzheimer’s disease.65,66 BChE has been detected histochemically in both senile plaques and neurofibrillary tangles in brains affected by Alzheimer’s disease.67–69

A variant of the BChE gene known as the BChE-K variant has a point mutation at nucleotide 1615 (GCA→ACA), resulting in a change of alanine 539 to threonine. This mutation reduces the catalytic activity of BChE by one third.70 Recently, it has been reported that the BChE-K variant is more common in patients with late onset Alzheimer’s disease than in controls, other dementias, and patients with early onset Alzheimer’s disease.71 The BChE-K variant was associated with a twofold increased risk of developing Alzheimer’s disease, with the strongest effect observed in the over 75 age group. When APOE ε4 carrier status was also taken into account, possession of both APOE ε4 and BChE-K alleles was found to be associated with a 36 times greater risk when compared with individuals with neither allele. However, two subsequent studies have failed to confirm this finding.72–75

**α, ANTICHYMOTRYSIN (ACT) GENE**

The presence of ACT in the cores of senile plaques, the high expression of ACT mRNA in brains affected by Alzheimer’s disease,76–78 and the ability of ACT to promote aggregation of Aβ fibrils,79–82 suggest an important role for ACT in the pathogenesis of Alzheimer’s disease. The ACT gene maps to chromosome 14q32.1, and contains a common biallelic polymorphism in the signal sequence, resulting in either an alanine (A) or a threonine (T) at position −17 of the ACT protein. It has been reported that the A allele of this signal sequence polymorphism is associated with an increased risk of Alzheimer’s disease in APOE ε4 carriers only.83 However, it has also been reported that the ACT/AA genotype is associated with an increased risk of Parkinson’s disease,84 a disease with similar pathology to Alzheimer’s disease. However, many studies in Alzheimer’s disease populations have failed to confirm the role of the ACT signal sequence A allele as a late onset disease risk factor,85–87 although Talbot and colleagues87 did observe that the combination of the APOE ε4 allele and the ACT/AA genotype may result in a lower age of onset.

The A10 allele of a polymorphic dinucleotide TC/TA repeat located in the 5’ flanking region of the ACT gene has also been reported to act as a risk factor for late onset Alzheimer’s disease, in association with APOE ε4.88,89 Strong linkage disequilibrium was observed between the A10 microsatellite allele and the ACT signal sequence T allele in both the control and Alzheimer’s disease groups. These findings are therefore contradictory to the reports of an association between the ACT A allele and Alzheimer’s disease.

**MITOCHONDRIAL DNA MUTATIONS**

Some evidence suggests that Alzheimer’s disease can show a pattern of maternal inheritance, whereby the offspring of mothers with Alzheimer’s disease have an increased risk of Alzheimer’s disease compared with offspring of affected fathers.90 Because mitochondrial DNA is maternally inherited, this implicates the involvement of mitochondrial DNA mutations in Alzheimer’s disease. However, studies of various mitochondrial DNA mutations that have been reported to influence the risk of Alzheimer’s disease have yielded inconsistent results.

Mutations in the cytochrome C oxidase genes COI and COII91 and in the ND2 gene, encoding subunit 2 of respiratory chain complex T19 have been reported to cause an increased risk of Alzheimer’s disease. However, several subsequent studies have failed to confirm these findings.117–119 A variant of a mitochondrial tRNA gene has also been reported to be associated with the late onset disease, again with conflicting results.119–122 It is possible that any observed mitochondrial DNA alterations in patients with Alzheimer’s disease occur as a result of the neurodegenerative process, rather than being heritable risk factors.

**OTHER LOCI?**

A complete genomic screen in familial late onset Alzheimer’s disease has identified four regions of interest in the genome, on chromosomes 4, 6, 12, and 20, with a region near the centromere of chromosome 12 showing the strongest linkage.77 In this study, the effect of the chromosome 12 locus appears to be greatest in families in which the APOE ε4 allele has little influence on the risk of Alzheimer’s disease. Although the LRP gene, a candidate Alzheimer’s disease risk factor, is located on chromosome 12, the Pericak-Vance study77 shows no significant association with this gene in either familial or sporadic disease groups. One study has also reported a potential locus on the X chromosome.123

**THE VALUE OF ASSOCIATION STUDIES**

It can be seen from the previous section on risk factors in Alzheimer’s disease that the results obtained from association studies have provided conflicting data in a number of instances. Of the more than 70 000 genes believed to be expressed in the brain it would be remarkably fortuitous if the ones currently known (just over 2000) included all those associated with the disease state. It is far more likely that other genetic risk factors for Alzheimer’s disease remain to be identified. However, the potential success of the association study approach is illustrated by the data obtained from APOE ε4 studies, which are robust and readily reproduced by many workers in the field.
A number of other factors could be contributing to the discrepancies noted in the literature. It is essential that the study groups used are closely matched for age, sex, and ethnic background because a number of alleles have been shown to vary with each of these parameters. There is also a problem with the accuracy of the diagnosis of Alzheimer's disease; although a clinical diagnosis of dementia is relatively straightforward, attributing a diagnosis of Alzheimer's disease is more problematic. A number of other pathologies (for example, Lewy body dementia, tangle only dementia, Pick's disease) present in a similar way and cannot be excluded easily on clinical grounds. Some would argue that all patients (both study and control groups) need to have their diagnoses confirmed histopathologically before inclusion in any study. It is quite possible that the genetics of these neuropathological diseases differ and inclusion of different phenotypes within a study group will obviously lead to a potential diminution of any association. Also, to increase the power of detection of any potential associations and resolve conflicting results between studies, study group sizes need to be increased substantially. Power calculations indicate that sample numbers should be in the thousands, rather than the hundreds, to detect potentially weak associations.

Another problem that needs to be addressed is how to accommodate the strong APOE e4 effect, which is apparent in all studies of late onset disease. Better mathematical models for complex multigenic disorders are required so that the APOE e4 effect can be removed and the effect of other loci established. This becomes even more important when the individual effect of a particular allele is small but in combination with other risk factors may become more potent. Synergy analysis attempts to address this issue and this type of approach might be useful in future association studies. Another approach would be to study only APOE e4 negative patients and controls, thereby eliminating the APOE e4 effect completely.

The late onset nature of Alzheimer's disease causes obvious difficulties with study design, making pedigree analysis almost impossible. Sibling studies, which are usually very informative, would be of less value in Alzheimer's disease, because knowledge of parental genotypes is desirable to draw any conclusions regarding a particular locus. Although association studies are prone to a number of very real problems, it seems that they are the best approach that can be applied to Alzheimer's disease at this time, and can yield valuable information, as demonstrated by APOE studies.

Pathogenesis of Alzheimer's disease

Cholinergic Hypothesis

It has been observed that there is a cholinergic deficit in Alzheimer's disease brains, with reduced concentrations of choline acetyltransferase and acetylcholinesterase. The extent of this deficiency seems to correlate with the density of lesions, with greatest reductions in choline acetyltransferase and acetylcholinesterase activities in areas of the brain with high numbers of senile plaques and neurofibrillary tangles. In addition, reduction in choline acetyltransferase activity of a similar magnitude to that seen typically in Alzheimer's disease has been reported in other neurodegenerative conditions, without associated severe cognitive decline. The cholinergic deficit probably only explains part of the observed cognitive decline in patients with Alzheimer's disease. Other neurotransmitter changes also occur, including reduction of noradrenaline and serotonin in the cerebral cortex.

Amyloid Cascade Hypothesis

This hypothesis states that the deposition of Aβ protein is the primary event in the pathogenesis of Alzheimer's disease, and that neurofibrillary tangles, neuronal death, and dementia occur subsequently as a result of this event. The cascade hypothesis assumes that Aβ and βAPP cleavage products containing Aβ are neurotoxic. Two successive events are required to cause Alzheimer's disease; first intact Aβ must be produced, and second this must facilitate or cause cell death and neurofibrillary tangle formation.

Aβ has been reported to have both neurotrophic and neurotoxic effects in vitro. The toxicity seems to depend on the fibrillar state of Aβ and can be attenuated by both apoE and ACT. Aggregated Aβ may either kill neurons directly or increase the vulnerability of neurons to other insults such as excitotoxicity, hypoglycaemia, and peroxidative damage. It has also been suggested that Aβ disrupts calcium homeostasis, resulting in increased concentrations of intraneuronal calcium. It has been shown that tau phosphorylation is regulated by intracellular calcium concentrations, therefore suggesting a mechanism by which Aβ causes neurofibrillary tangle formation.

The amyloid cascade hypothesis is supported by the presence of familial Alzheimer's disease mutations in βAPP that apparently alter βAPP processing and favour amyloid plaque formation. The fact that individuals with Down's syndrome (trisomy 21) develop Alzheimer's disease-like pathology early in life also shows that overexpression of βAPP can cause Alzheimer's disease pathology, supporting a central role for Aβ deposition in Alzheimer's disease.

It has been suggested that the presenilin familial Alzheimer's disease mutations also cause disease by altering the processing of βAPP in a similar way to mutations in the βAPP gene itself. It has been demonstrated...
Genetic risk factors in Alzheimer’s disease

that both PS-1 and PS-2 familial Alzheimer’s disease mutations cause an increase in the concentration of Aβ42, therefore leading to increased amyloid deposition. Other genetic and environmental factors might act on the cascade at this point by stimulating aggregation of Aβ—for example, both apoE and ACT can enhance aggregation of Aβ in vitro. The potential effects of both genetic and environmental factors on the amyloid cascade are depicted in fig 3.

HYPERPHOSPHORYLATION OF TAU AND NEUROFIBRILLARY TANGLE FORMATION

The main argument against the amyloid cascade hypothesis is that neurofibrillary tangle formation has been shown to precede Aβ deposition, and densities of neurofibrillary tangles, rather than senile plaques, correlate closely with the extent of intellectual decline in patients with Alzheimer’s disease. The presence of neurofibrillary tangles in the absence of amyloid deposits (for example in Parkinson’s disease) demonstrates that amyloid is not an absolute prerequisite for neurofibrillary tangle formation.

Neurofibrillary tangles are composed mainly of a hyperphosphorylated form of the tau protein. Tau is a microtubule associated protein present in both the central and peripheral nervous systems. In the brain it is found predominantly in the axons of nerve cells, and its normal function is to promote the assembly and stability of microtubules by binding to tubulin. Native tau is a phosphoprotein, and the affinity of tau for microtubules appears to be regulated by the level of phosphorylation. In brains of patients with Alzheimer’s disease, tau becomes hyperphosphorylated and its ability to bind microtubules is greatly reduced, thus leading to destabilisation of the microtubule system. This could lead to diminished axoplasmic flow and, therefore, a reduced supply of substrates to the axons and dendrites, resulting in neuronal death. Hyperphosphorylated tau, being unable to bind microtubules, is therefore available to assemble into paired helical filaments.

APOE genotype has been reported to influence tau hyperphosphorylation, with the apoE ε3 protein, but not ε4, being capable of binding to tau and preventing hyperphosphorylation. This suggests a possible mechanism for the increased risk associated with possession of the APOE ε4 allele.

ACUTE PHASE RESPONSE

The presence of ACT, an acute phase protein, in amyloid plaques and neurofibrillary tangles and neuronal death. Ultimately, this leads to the symptoms of dementia. FAD, familial Alzheimer’s disease.

Figure 3 The amyloid cascade hypothesis: genetic and environmental factors act in combination to increase amyloid deposition, resulting in formation of senile plaques, neurofibrillary tangles and neuronal death. Ultimately, this leads to the symptoms of dementia. FAD, familial Alzheimer’s disease.
also been demonstrated to induce apoptosis in cultured neurons.\textsuperscript{164} 165 Alzheimer's disease because of the ability of Aβ to induce apoptosis in cultured neurons,\textsuperscript{171} 172 as well as in Alzheimer's disease brains.\textsuperscript{175} 176 Advanced glycation endproducts are a heterogeneous group of adducts arising via non-enzymatic reactions between reducing sugars and amine groups on proteins. This modification is irreversible, and advanced glycation endproducts accumulate during normal aging.\textsuperscript{173} 176 Advanced glycation endproducts have been implicated in the pathogenesis of Alzheimer's disease; diseased brains have been

---

**OXIDATIVE PHOSPHORYLATION DEFECTS**

Oxidative phosphorylation (OXPHOS) generates mitochondrial ATP and is the main source of energy for a number of organs and tissues including brain, muscle, heart, kidney, and liver. The OXPHOS system is known to decline with age,\textsuperscript{159} 160 possibly as a result of accumulation of damage to mitochondrial DNA caused by oxygen free radicals, a byproduct of OXPHOS. Evidence suggests that OXPHOS defects may play a role in the pathogenesis of Alzheimer's disease. It has been shown that patients with Alzheimer's disease have OXPHOS defects in a number of tissues.\textsuperscript{166} 167 Mitochondrial DNA mutations have been reported to influence the risk of Alzheimer's disease, and could lead to an increased rate of age related decline in the OXPHOS system.

**APOPTOSIS**

Apoptosis is a form of cell death characterised by condensation of nuclear chromatin, cytoplasmic condensation, DNA fragmentation, and maintenance of membrane integrity. Extensive loss of neurons is characteristic of certain areas of the Alzheimer's disease brain, but the mechanism of this neuronal cell death is unknown. Apoptosis has been implicated in Alzheimer's disease because of the ability of Aβ to induce apoptosis in cultured neurons.\textsuperscript{164} 165 Familial Alzheimer's disease mutant APP has also been demonstrated to induce apoptosis in vitro,\textsuperscript{166} and mutations in both PS-1 and PS-2 sensitize cells to pro-apoptotic stimuli.\textsuperscript{157} 158 Increased concentrations of the apoptosis promoting protein Bax have been reported in response to Aβ in vitro,\textsuperscript{166} and in Alzheimer's disease neurons in vivo.\textsuperscript{169}

However, the proportion of neurons in brains affected by Alzheimer's disease that actually die by apoptosis rather than necrosis is not known. DNA fragmentation has been observed in Alzheimer's disease brain cells,\textsuperscript{159} 170; however, most of these neurons lack the characteristic morphological features of apoptosis.\textsuperscript{171} 172 The assay of apoptosis specific protein, a marker for late stage apoptosis in Alzheimer's disease brains suggests that most dystrophic neurons in affected brains exhibit necrosis rather than apoptosis.\textsuperscript{173}

**FRAMESHIFT MUTATIONS**

Dinucleotide deletions (ΔGA) within GAGAG motifs of the βAPP and ubiquitin B (Ubi-B) genes have been suggested to play a role in both early and late onset sporadic Alzheimer's disease.\textsuperscript{174} Frameshift mutations appear to be introduced during protein synthesis that are not present in genomic DNA. Aberrant forms of βAPP and Ubi-B proteins were found to be more prominent in Alzheimer's disease brains than in control brains.

The mechanism by which a wild-type gene can give rise to a mutant protein is unclear. It could be via a defect during transcription, or an editing mechanism in the RNA (fig 5). Presumably, aberrant proteins arising from errors during protein synthesis would accumulate with age, possibly explaining the increased risk of Alzheimer's disease with age. However, it is possible that the mutant proteins arise as a result of damage already present in the Alzheimer's disease brain, rather than being a causative factor in the disease.

**ADVANCED GLYCATION ENDPRODUCTS**

Advanced glycation endproducts are a heterogeneous group of adducts arising via non-enzymatic reactions between reducing sugars and amine groups on proteins. This modification is irreversible, and advanced glycation endproducts accumulate during normal aging.\textsuperscript{173} 176 Advanced glycation endproducts have been implicated in the pathogenesis of Alzheimer's disease; diseased brains have been
reported to contain significantly higher concentrations of advanced glycation endproducts than age matched control brains and advanced glycation endproduct modified AP has been demonstrated to accelerate amyloid aggregation in vitro.\textsuperscript{177} Advanced glycation endproducts colocalise with apoE, and it has been hypothesised that advanced glycation endproduct modified proteins bind to apoE and contribute to the formation of senile plaques.\textsuperscript{178} A greater binding affinity for advanced glycation endproducts has been demonstrated with apoE ε4 compared with apoE ε3, and this might have pathogenic consequences in vivo.\textsuperscript{179}

Summary

Although new discoveries are being made constantly in this field, the pathogenesis of Alzheimer’s disease remains poorly understood. The question remains, what causes Alzheimer’s disease and why do some individuals develop the disease while others live into old age with no signs of dementia? Molecular genetic research has shown that there is no simple answer to this question. Alzheimer’s disease remains poorly understood in this field, the pathogenesis of Alzheimer’s disease—an immunohistochemical study with monoclonal antibodies against native and inactivated alpha-1-antichymotrypsin. Acta Neuropathol 1991;82:497–501.

We thank Dr K Robson and Professor J Lowe (Division of Pathology, School of Clinical Laboratory Sciences, Queen’s Medical Centre, Nottingham) for providing the photographs used in this article. We would also like to thank the Trent Health Research Development Scheme for financial support and Nottingham University for the studentship for L.T. 1


et al. 64 Okuizumi K, Onodera O, Namba Y, et al.

et al. 61 Itzhaki RF, Lin WR, Shang DH, et al.

et al. 60 Song YQ, Rogaeva E, Premkumar S, et al.


et al. 52 Corder EH, Saunders AM, Strittmatter WJ, et al.


et al. 45 Saunders AM, Strittmatter WJ, Schmechel D, et al.

et al. 44 Roses AD, Saunders AM, Strittmatter WJ, et al.

et al. 43 Corder EH, Saunders AM, Strittmatter WJ, et al.

et al. 49 Tsai MS, Tangalos EG, Petersen RC, et al.


et al. 52 Corder EH, Saunders AM, Strittmatter WJ, et al.


et al. 54 Roses AD, Saunders AM, Strittmatter WJ, et al.


et al. 56 Song YQ, Rogaeva E, Premkumar S, et al.


et al. 58 Corder EH, Saunders AM, Risch NJ, et al.


et al. 60 Song YQ, Rogaeva E, Premkumar S, et al.

et al. 61 Itzhaki RF, Lin WR, Shang DH, et al.

et al. 62 Corder EH, Saunders AM, Risch NJ, et al.

et al. 63 Corder EH, Saunders AM, Risch NJ, et al.

et al. 64 Okuizumi K, Onodera O, Namba Y, et al.

et al. 65 Corder EH, Saunders AM, Strittmatter WJ, et al.

et al. 66 Kim SH, Good ED, Scharfman HE, et al.

et al. 67 Michel PB, Poirier J, Davignon J, et al.


et al. 69 Michel PB, Poirier J, Davignon J, et al.

et al. 70 Rebeck GW, Harr SD, Strickland DK, et al.


et al. 95 Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Am J Pathol 1997;150:991–1000.


